Renowned Scientist to Lead Tularemia Research at Boston University Medical Center

in Health & Medicine, News Releases, School of Medicine
February 25th, 2005

Contact: Robert Brogna, (617) 638-8491 | Robert.Brogna@bmc.org

(Boston) – Renowned research scientist Dr. John R. Murphy has been named the Principal Investigator of a grant from the National Institute of Allergy and Infectious Diseases to study tularemia, it was announced today by Boston University Medical Center (BUMC) officials. Dr. Murphy, a resident of the South End neighborhood in Boston, will be responsible for the administration of the tularemia grant over the next four years.

The grant provides funding for research on development of a vaccine and better tests for early diagnosis of tularemia, also known as rabbit fever.

“Dr. Murphy’s exemplary track record in designing scientific experiments and his insistence on fostering and implementing a culture of biosafety in laboratory settings highly recommended him for this position,” said Dr. Thomas J. Moore, acting provost of BUMC. “We believe that Jack Murphy’s appointment will help BUMC maintain a position of leadership in this important research.”

Dr. Murphy brings stellar research credentials to this position. He has over 30 years of laboratory experience working on the molecular basis of pathogenesis, including field research in India and Bangladesh, as well as extensive experience working under Biosafety Levels 3 and 4 containment. He is currently a Professor of Medicine, Microbiology, a Research Professor of Biochemistry at the Boston University School of Medicine and a Professor of Biomedical Engineering in the College of Engineering at Boston University.

He was an associate professor in microbiology and molecular genetics at the Harvard Medical School from 1977-1983.

Dr. Murphy worked at the National Institutes of Health complex at Fort Detrick, Maryland, where his groundbreaking experiments with diphtheria toxins led to the development of the cancer-fighting drug Ontak, often prescribed for those patients suffering from leukemia and lymphoma.

Comments are closed.